ANTIDIABETICS AND FIBRATES - REPAGLINIDE
The combination of gemfibrozil and repaglinide results in a marked pharmacokinetic interaction that can result in serious hypoglycaemia.
On the basis of studies and reports of serious hypoglycaemic episodes with gemfibrozil and repaglinide, the European Medicines Agency contraindicate concurrent use.
On the basis of studies and reports of serious hypoglycaemic episodes with gemfibrozil and repaglinide, the European Medicines Agency contraindicate concurrent use.